Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 292-299

  Krüger, Achim ^a,c   Soeltl, Rita ^a   Lutz, Verena ^a   Wilhelm, Olaf G ^a,b   Magdolen, Viktor ^a   Rojo, Elena E ^a   Hantzopoulos, Petros A ^a   Graeff, Henner ^a   Gänsbacher, Bernd ^a   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Wilex Biotechnology GmbH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; CD87; Metastasis; Plasminogen; Soluble uPA receptor; Tumor; uPA

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; TREATMENT OUTCOME;

ANIMALIA; MUS MUSCULUS;

EID: 0039770451     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700144     Document Type: Article

References (33)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
2. Chapman HA, Riese RJ, Shi G-P. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol. 1997;59:63-88.
3. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG. Matrix metalloproteinases: novel targets for directed cancer therapy. Drugs Aging. 1997;11:229-244.
4. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997;78:285-296.
5. Luther T, Magdolen V, Albrecht S, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol. 1997;150:1231-1244.
6. Hildenbrand R, Glienke W, Magdolen V, et al. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 1998;110:27-32.
7. Jankun J, Merrick HW, Goldblatt PJ. Expression and localization of elements of the plasminogen activation system in benign disease and breast cancers. J Cell Biochem. 1993;53:135-144.
8. 2-macroglobulin receptor in human breast carcinomas. Int J Cancer. 1996;66:441-452.
9. Ellis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation: receptor binding has no influence on the zymogenic nature of pro-urokinase. J Biol Chem. 1996;271:14779-14784.
10. Festuccia C, Dolo V, Guerra F, et al. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis. 1998;16:513-528.
11. Mazzieri R, Masiero L, Zanetta L, et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 1997;16:2319-2332.
12. Bugge TH, Kombrinck KW, Xiao Q, et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood. 1997;90:4522-4531.
13. Solberg H, Romer J, Brünner N, et al. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer. 1994;58:877-881.
14. Resnati M, Guttinger M, Valcamonica S, et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996;15: 1572-1582.
15. Fischer K, Lutz V, Wilhelm O, et al. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett. 1998;438:101-105.
16. Reuning U, Magdolen V, Wilhelm O, et al. Multifunctional potential of the plasminogen activation system in tumor growth and metastasis. Int J Oncol. 1998;13:893-906.
17. Dumler I, Kopmann A, Weis A, et al. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19: 290-297.
18. Wilhelm O, Weidle U, Hohl S, et al. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA): inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 1994; 337:131-134.
19. Brünner N, Thompson EW, Spang-Thomsen M, et al. lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer. 1992;28A:1989-1995.
20. Turkmen B, Schmitt M, Schmalfeldt B, et al. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis. 1997;18:686-689.
21. Fridman R, Sweeney TM, Zain M, et al. Malignant transformation of NIH-3T3 cells after subcutaneous co-injection with a reconstituted basement membrane (matrigel). Int J Cancer. 1992;51:740-744.
22. Goretzki L, Bognacki J, Koppitz M, et al. Quantitative assessment of interaction of urokinase-type plasminogen activator and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay. Fibrinolysis Proteolysis. 1997;11: 11-19.
23. Krüger A, Fata JE, Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood. 1997;90:1993-2000.
24. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA. 1998;95:8795-8800.
25. Eitzman DT, Krauss JC, Shen T, et al. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood. 1996;87:4718-4722.
26. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923-928.
27. Krüger A, Sanchez-Sweatman OH, Martin DC, et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene. 1998;16:2419-2423.
28. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs. 1997;15:175-185.
29. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998;4:1101-1109.
30. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, et al. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis. 1996;14:297-307.
31. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res. 1990;50:5997-6001.
32. Baramova EN, Bajou K, Remacle A, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997;405:157-162.
33. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science. 1996; 273:1551-1555.